Published in Genes Dev on December 17, 2015
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics (2011) 25.76
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol (2009) 8.63
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Stem cells and cancer; the polycomb connection. Cell (2004) 7.43
Metastasis: a question of life or death. Nat Rev Cancer (2006) 6.26
Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest (2005) 5.90
Selection of successive tumour lines for metastasis. Nat New Biol (1973) 5.03
EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments. Bioinformatics (2013) 4.79
Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat Cell Biol (2010) 4.04
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature (2014) 3.80
Bmi1, stem cells, and senescence regulation. J Clin Invest (2004) 3.80
In vivo switching of human melanoma cells between proliferative and invasive states. Cancer Res (2008) 3.66
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem (2007) 3.24
Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst (2006) 3.17
Mitf regulation of Dia1 controls melanoma proliferation and invasiveness. Genes Dev (2006) 2.87
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer (2014) 2.54
The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest (2009) 2.52
Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res (2010) 2.43
Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A (2009) 2.41
β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell (2011) 2.17
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. Nat Commun (2014) 2.10
The WNT/Beta-catenin pathway in melanoma. Front Biosci (2006) 2.09
Proinvasion metastasis drivers in early-stage melanoma are oncogenes. Cancer Cell (2011) 1.99
Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res (2008) 1.99
Integrative genome comparison of primary and metastatic melanomas. PLoS One (2010) 1.97
MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene (2011) 1.94
Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc Natl Acad Sci U S A (2008) 1.90
The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene (2009) 1.75
Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle (2006) 1.69
Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer (2007) 1.62
A re-evaluation of the "oncogenic" nature of Wnt/beta-catenin signaling in melanoma and other cancers. Curr Oncol Rep (2010) 1.52
Activation of Vav/Rho GTPase signaling by CXCL12 controls membrane-type matrix metalloproteinase-dependent melanoma cell invasion. Cancer Res (2006) 1.49
In melanoma, beta-catenin is a suppressor of invasion. Oncogene (2011) 1.40
Polycomb group genes as epigenetic regulators of normal and leukemic hemopoiesis. Exp Hematol (2003) 1.35
FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells. Breast Cancer Res Treat (2011) 1.22
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest (2014) 1.16
Polycomb group proteins in the DNA damage response: a link between radiation resistance and "stemness". Cell Cycle (2011) 1.14
Systematic classification of melanoma cells by phenotype-specific gene expression mapping. Pigment Cell Melanoma Res (2012) 1.14
miR-200c inhibits melanoma progression and drug resistance through down-regulation of BMI-1. Am J Pathol (2012) 1.13
The small GTPase ARF6 stimulates β-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci Signal (2013) 1.10
Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus. Sci Signal (2012) 1.06
Chromosome instability modulated by BMI1-AURKA signaling drives progression in head and neck cancer. Cancer Res (2012) 1.04
Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol (2008) 1.00
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget (2014) 0.94
MITF Modulates Therapeutic Resistance through EGFR Signaling. J Invest Dermatol (2015) 0.91
The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther (2011) 0.89
PHF19 and Akt control the switch between proliferative and invasive states in melanoma. Cell Cycle (2012) 0.89
The ZEB1 transcription factor acts in a negative feedback loop with miR200 downstream of Ras and Rb1 to regulate Bmi1 expression. J Biol Chem (2013) 0.87
Bmi1 is required for tumorigenesis in a mouse model of intestinal cancer. Oncogene (2013) 0.84